Nemaura Medical to Present at the H.C. Wainwright Global Hybrid Investment Conference

Rhea-AI Summary

Nemaura Medical (NASDAQ: NMRD) announced that CEO Dr. Faz Chowdhury will present virtually at the H.C. Wainwright Global Hybrid Investment Conference from May 23 – 26, 2022. The presentation is scheduled for May 24, 2022, available on demand starting at 7:00am ET. Dr. Chowdhury will discuss recent business developments and engage in one-on-one investor meetings. Nemaura specializes in wearable diagnostic devices, focusing on sugarBEAT®, a non-invasive glucose monitor, and the proBEAT™ system, integrating AI for diabetes management.

Loughborough, England, May 19, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces today that CEO Dr. Faz Chowdhury will present virtually at the H.C. Wainwright Global Hybrid Investment Conference. The conference is being held on May 23 – 26, 2022 at the Fontainebleau Hotel in Miami Beach, FL.

Presentation Date: May 24, 2022

Time: On demand as of 7:00am ET

Dr. Chowdhury will provide updates on recent business developments. In addition, Dr. Chowdhury will be available for one-on-one meetings with investors who are registered to attend the conference. To request a meeting and to register for the conference, click below:

In-Person

Virtual 

About Nemaura Medical, Inc.

Nemaura Medical, Inc. is a medical technology company developing and commercializing wearable diagnostic devices. The company is currently commercializing sugarBEAT^® and proBEAT^™. sugarBEAT^®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT^® to the U.S. FDA. proBEAT^™ combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service and has been launched in the U.S. as a general wellness product as part of its BEAT^® diabetes program that is currently undergoing pilot studies.

Additionally, Nemaura has launched Miboko, a new metabolic health and well-being program using a non-invasive glucose sensor along with an AI mobile application that helps a user understand how certain foods and lifestyle habits can impact one’s overall metabolic health and well-being. Nemaura believes that up to half the population could benefit from a sensor and program that monitors metabolic health and well-being.

The Company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023.

For more information, please visit www.NemauraMedical.com.

Contact:

Jules Abraham
CORE IR
917-885-7378
julesa@coreir.com

FAQ

What is the presentation date for Nemaura Medical at the H.C. Wainwright Conference?

The presentation date for Nemaura Medical is May 24, 2022.

What time will Nemaura Medical's presentation be available?

Nemaura Medical's presentation will be available on demand starting at 7:00am ET.

Who will present for Nemaura Medical at the conference?

Dr. Faz Chowdhury, CEO of Nemaura Medical, will present at the conference.

Is Dr. Chowdhury available for meetings during the conference?

Yes, Dr. Chowdhury will be available for one-on-one meetings with registered investors.

What does Nemaura Medical specialize in?

Nemaura Medical specializes in developing wearable diagnostic devices, including glucose monitors.